• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

Bladder Cancer Drug Pipeline Update 2015

  • ID: 1197078
  • June 2015
  • Region: Global
  • Bioseeker

According to the American Cancer Society, bladder cancer is the 6th most common cancer in the U.S. Bladder cancer occurs among both men and women. When found and treated early, the 5 year survival rate is 94%.
There are today 122 companies plus partners developing 149 drugs targeting bladder cancer in development. In addition, there are 3 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 40 drugs. Bladder Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 123 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 118 out of the 120 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 45 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.

How May Drug Pipeline Update Be READ MORE >

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown


Our Clients

Novartis AG Roche Diagnostics Ltd. Genentech, Inc. Photocure ASA Bristol-Myers Squibb Eli Lilly and Company